Leading Australian life science venture firm announces appointment of Duncan Mackintosh to lead New Zealand operations
Melbourne, Australia and Auckland, New Zealand - July 26, 2016 – Brandon Capital Partners, one of Australia’s leading life science venture capital firms, today announced the expansion of its operations into
New Zealand. The firm also announced that Duncan Mackintosh, a leader in technology commercialisation, has been
appointed as Investment Manager and will lead New Zealand operations.
Brandon Capital Partners manages the Medical Research Commercialisation Fund (MRCF), a unique investment collaboration between major Australian superannuation funds and more than 50 of Australia’s
leading medical research institutes and research hospitals. The MRCF was established to provide dedicated investment
funding and expertise to support the development of very early stage research innovations. Since 2007, the MRCF has
supported the development of 27 start-up companies developing technologies originating from members, with some notable
successes, such as Spinifex Pharmaceuticals which was acquired by Novartis for US$725 million in 2015, and Fibrotech
Therapeutics, which was acquired by Shire for $557 million (USD) in 2014.
In February 2016 Science and Innovation Minister Steven Joyce announced that New Zealand had joined Australia’s Medical
Research Commercialisation Fund (MRCF), enabling New Zealand research organisations to become members of the fund and
seek investment support for their emerging technologies from the third MRCF fund, an AU$200 million fund.
“Internationally, New Zealand ranks very highly in terms of its medical innovations and we are therefore excited to be
expanding the MRCF to include New Zealand members. At $200M, our latest fund has the capacity to support the best
research opportunities from across New Zealand and Australasia, from discovery to clinical development and
commercialisation,” said Dr. Chris Nave, Managing Director of Brandon Capital Partners and Principal Executive of the
MRCF.
“The expansion of MRCF’s membership network increases the opportunity for collaboration, capability sharing and
knowledge aggregation. With key international linkages, including our newly established US office in the San Francisco
Bay Area, the MRCF is providing access to key resources which overcome some of the key factors impeding the successful
commercialisation of research discoveries in Australia and New Zealand. Building a presence in New Zealand is a key part
of our goal to becoming a significant international life sciences fund. We’re delighted to have secured someone with
Duncan’s extensive industry networks and strong record of achievement in the life science sector, to lead our NZ
activities.”
Duncan Mackintosh has specialised in the development and commercialisation of life sciences and technology for the past
15 years, with his most recent role as Chief Executive of WaikatoLink, the commercial arm of the University of Waikato.
He has co-founded a number of companies including Ligar Polymers LP, PA Therapeutics LLC, Aldera Animal Health, and
Novatein which was later incorporated into Aduro Biopolymers. He was also a Co-Founder and founding Investment Committee
Member of KiwiNet, a research commercialisation consortium. He holds a BVSc in Veterinary Science from Massey University
and is a graduate of Lincoln University’s Kellogg Rural Leadership Programme.
Mackintosh says, “We have a very vibrant bio sector here in New Zealand with some first class life sciences researchers
and research, which we’re looking forward to supporting. The MRCF funding helps promising technologies bridge the
current market failure, the so called ‘Valley of Death’, enabling them to progress beyond grant funding to a point where
they have achieved clinical or prototype proof of concept and/or market validation.”
Mackintosh says a priority is for New Zealand’s research organisations to sign up to gain access to the MRCF. “Member
Institutes can then identify opportunities within their institute and bring them forward to the Investment Review
committee.”
Early-stage opportunities can receive up to $3 million (AUD) to support preclinical development, with those successfully
progressing through this stage able to receive a further $17 million (AUD) in investment support.
ENDS